Amid national angst over the cost of prescription drugs, a new analysis finds that U.S. consumers and insurers last year paid anywhere from two to four times as much for 20 brand-name medicines than what were paid in Australia, Canada, and France.
For instance, the cost for a one-month supply of the Xarelto, which is used to combat blood clots, was $272 in the U.S. for those with some form of health insurance, but between $64 and $78 in the other countries. A three-month supply of the Imbruvica cancer pill cost an estimated $13,809 in the U.S., while cancer patients in the other three countries paid between $6,011 and $7,120.
About the Author Reprints
